ARV-110 is a first-in-class PROTAC that effectively targets the wild type Androgen Receptor (AR) and certain genomic alterations of the AR (amplification, T878A, H875Y, F877L, M895V, but not L702H or AR-V7) for degradation in both enzalutamide sensitive and resistant preclinical models. ARV-110 showed promising anti-tumor activity in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC).
Androgen Receptor Inhibitors Related Products:
Chlormadinone acetate; Bicalutamide; Apalutamide; Galeterone; Cyproterone acetate; AZD-3514; Spironolactone; Darolutamide; Megestrol Acetate; Clascoterone; RU-58841; Enzalutamide